Department of Reproductive Biology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Women's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Syst Biol Reprod Med. 2021 Jun;67(3):177-188. doi: 10.1080/19396368.2020.1862357. Epub 2021 Feb 25.
Administration of platelet-rich plasma (PRP) is one of the well-recommended strategies for the treatment of endometrium- and ovary-associated infertility. Due to the autologous source of PRP, minimal risks for disease transmission and immunogenic and allergic responses are expected in this method. Despite the extensive use of PRP in medicine, its precise mechanism of action in endometrial and ovarian tissues is still unknown. Nevertheless, the induction of cell proliferation, chemotaxis, regeneration, extracellular matrix synthesis, remodeling, angiogenesis, and epithelialization are the main pathways for PRP to affect female reproductive organs. Given the promising results of previous studies, it is necessary to standardize PRP preparation protocols for different therapeutic purposes and also clearly determine appropriate inclusion and exclusion criteria for recruiting patients. In the current review, we presented a summary of studies on PRP therapy for endometrium- and ovary-associated infertility with a focus on the possible mechanisms by which PRP enhances endometrial receptivity and regenerates ovarian function.: PRP: platelet-rich plasma; ART: assisted reproductive technology; POF: premature ovarian failure; TGF: transforming growth factors; PDGF: platelet-derived growth factors; IGF-I: insulin-like growth factor-1; HGF: hepatocyte growth factor; EGF: epidermal growth factor; FGF: fibroblast growth factor; VEGF: vascular endothelial growth factor; ADP: adenosine diphosphate, ATP: adenosine triphosphate; PDGF: platelet-derived growth factor; COX2: cyclooxygenase-2; TP53: tumor protein 53; ER-α: estrogen receptors alpha; ER-β: estrogen receptors beta; PR: progesterone receptor; RIF: recurrent implantation failure; G-CSF: granulocyte colony-stimulating factor; iNOS: inducible nitric oxide synthase; NF-kβ: nuclear factor kappa beta; MMPs: matrix metalloproteinases; Col1a1: collagen type I alpha 1; IL: interleukin; FSH: follicle-stimulating hormone; AMH: anti-Mullerian hormone; GDF-9: growth differentiation factor 9.
富血小板血浆(PRP)的应用是治疗子宫内膜和卵巢相关不孕的推荐策略之一。由于 PRP 是自体来源,因此这种方法预计疾病传播、免疫原性和过敏反应的风险最小。尽管 PRP 在医学中得到了广泛应用,但它在子宫内膜和卵巢组织中的确切作用机制仍不清楚。然而,细胞增殖、趋化性、再生、细胞外基质合成、重塑、血管生成和上皮化的诱导是 PRP 影响女性生殖器官的主要途径。鉴于先前研究的有希望的结果,有必要针对不同的治疗目的标准化 PRP 制备方案,并明确确定招募患者的适当纳入和排除标准。在本综述中,我们总结了 PRP 治疗子宫内膜和卵巢相关不孕的研究,重点介绍了 PRP 增强子宫内膜容受性和再生卵巢功能的可能机制。